James R Mercer

US Patent:

45377758, Aug 27, 1985

Filed:

Aug 13, 1982

Appl. No.:

6/407808

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

514398

Abstract:

The administration internally to humans of 1-(B-hydroxethyl)-2-methyl-5-nitroimidazole, (metronidazole) in a dosage range for adult humans of about 31-2,500 mgs per twenty-four hour period, is an effective therapeutic treatment for certain viral infections causing diverse symptoms, both acute and chronic. Corresponding dosage proportional to body weight appears effective in other mammals also.

US Patent:

39521036, Apr 20, 1976

Filed:

Oct 15, 1974

Appl. No.:

5/514798

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

424273

Abstract:

The administration internally to humans of 1-(. beta. -hydroxethyl)-2-methyl-5-nitromidazole, (metronidazole) in a dosage range for adult humans of about 31 to 1,000 mgs per twenty-four hour period, is an effective therapeutic treatment certain of viral infections.

US Patent:

40739287, Feb 14, 1978

Filed:

Feb 9, 1976

Appl. No.:

5/656336

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

424273R

Abstract:

The administration internally to humans of 1-(. beta. -hydroxyethyl)-2-methyl-5-nitromidazole, (metronidazole) in a dosage range for adult humans of about 31 to 2,500 mgs per 24 hour period, is an effective therapeutic treatment for viral regional ileitis.

US Patent:

49525948, Aug 28, 1990

Filed:

Jun 14, 1988

Appl. No.:

7/206651

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415
A61K 3152
A61K 31425

US Classification:

514398

Abstract:

The administration internally to humans of certain imidazol derivatives, especially 1-(Beta-hydroxyethyl)-2-methyl-5-nitro-imidazole (metgronidazole); N"-cyano-N-methyl-N'-[2[[(5-methyl-1H-imidazol-4-yl) methyl]thio]ethyl]-guanidine (cimetidine); 6-[1-methyl-4-nitro-imidazol-5-yl)thio] purine (azathioprine); L-(-)-2,3,5,6-Tetrahydro-6-phenyl-imidazo[2,1-b]thiazole (levamisole), or salts of the above compounds, is an effective therapeutic treatment for multiple sclerosis, both acute and chronic. The imidazole moeity is theorized to directly inhibit spread of the virus theorized to cause multiple sclerosis. Treatment of multiple sclerosis with metronidazole with one bolus dose on a frequency of once a day or less and with cimetidine on a frequency of twice per day has been found to be highly efficatious with minimal suppression of the patient's natural immune system and minimal long term peripheral nerve damage.

US Patent:

41772814, Dec 4, 1979

Filed:

Feb 10, 1978

Appl. No.:

5/876618

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

424273R

Abstract:

The administration internally to humans of 1-(. beta. -hydroxethyl)-2-methyl-5-nitromidazole, (metronidazole) in a dosage range for adult humans of about 31 to 2,500 mgs per twenty-four hour period, is an effective therapeutic treatment for measles.

US Patent:

48717592, Oct 3, 1989

Filed:

Apr 4, 1985

Appl. No.:

6/720021

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

514398

Abstract:

A method of treatment for mesenteric adenitis in humans is provided. The method comprises the administration of antiviral agents comprising pharmaceutical derivatives of imidazole. Specifically, mesenteric adenitis is treated with orally administered dosages of metronidazole or cimetidene. When the treatment is with metronidazole, a preferred dosage for average sized adult humans is approximately 1,000 to 2,000 milligrams administered once a day. When the antiviral agent administered is cimetidine, the preferred dosage is 900 to 1,200 milligrams given two times a day. When either cimetidine or metronidazole are given, concurrent treatment with zinc is suggested as a method of speeding recovery.

US Patent:

43460950, Aug 24, 1982

Filed:

Aug 6, 1979

Appl. No.:

6/064072

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

424273R

Abstract:

The administration internally to humans of 1-(B-hydroxethyl)-2-methyl-5-nitromidazole, (metronidazole) in a dosage range for adult humans of about 31 to 2,500 mgs per twenty-four hour period, is an effective therapeutic treatment for certain viral infections causing diverse symptoms both acute and chronic. Corresponding dosage proportional to body weight appears effective in other mammals also.

US Patent:

51029022, Apr 7, 1992

Filed:

May 1, 1990

Appl. No.:

7/517082

Inventors:

James B. Mercer - Lenexa KS

International Classification:

A61K 31415

US Classification:

514400

Abstract:

The administration internally to humans of certain imidazol derivatives, especially N"-cyano-N-methyl-N'-[2[[(5-methyl-1H-imidazol-4-yl) methyl]thio]-ethyl]-guanidine (cimetidine) or salts thereof, is an effective therapeutic treatment for multiple sclerosis, both acute and chronic. The imidazole moiety is theorized to directly inhibit spread of the virus theorized to cause multiple sclerosis. Treatment of multiple sclerosis with metronidazole with one bolus dose on a frequency of once a day or less and with cimetidine on a frequency of twice per day has been found to be highly efficatious with minimal suppression of the patient's natural immune system and minimal long term peripheral nerve damage.